MedTrace Logo

Aloe Vera in Irritable Bowel Syndrome

NCT01400048 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2018-09-10

No results posted yet for this study

Summary

The purpose of the present study is to study the effect of aloe vera in the treatment of IBS patients in a randomized, double-blind placebo controlled study.

Conditions

  • Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

Aloe vera effervescent tablet (AVH200)

250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®

DIETARY_SUPPLEMENT

Placebo control

60mg Ascorbic acid

Sponsors & Collaborators

  • Calmino group AB

    collaborator UNKNOWN

  • Sahlgrenska University Hospital

    lead OTHER

Principal Investigators

  • Magnus Simrén, MD, PhD · Dept of Internal medicine, Sahlgrenska UH, Gothenburg, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2016-12-31
Completion
2017-03-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01400048 on ClinicalTrials.gov